Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2003

Study Completion Date

January 31, 2006

Conditions
Melanoma
Interventions
DRUG

ILX651

Trial Locations (19)

12208

US Oncology / Albany Regional Cancer Center, Albany

29615

US Oncology / Cancer Centers of the Carolinas, Greenville

32806

US Oncology / Cancer Centers of Florida, Orlando

45409

US Oncology / Dayton Oncology and Hematology, Kettering

63141

Center for Cancer Care Research, St Louis

64111

US Oncology / Kansas City Oncology and Hematology, Kansas City

66210

US Oncology / Kansas City Oncology, Overland Park

75246

US Oncology / Mary Crowley Medical Research, Dallas

75702

US Oncology/ Tyler Cancer Center, Tyler

76104

US Oncology /Texas Oncology, Fort Worth

77030

St. Luke's Episcopal Hospital, Houston

80010

Univ of Colorado Cancer Center/ Anschutz Cancer, Aurora

85285

Arizona Cancer Center at Scottsdale, Scottsdale

85724

Univ of Arizona Cancer Center, Tucson

90033

USC / Norris Cancer Center, Los Angeles

90404

Cancer Institute Medical Group, Santa Monica

98109

Seattle Cancer Care Alliance, Seattle

99218

US Oncology / Cancer Care Northwest, Spokane

02215

Beth Israel Medical Center, Boston

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00068211 - Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma | Biotech Hunter | Biotech Hunter